Business Context and Reporting Period
This Form 8-K is filed by Obalon Therapeutics, Inc. (trading symbol: OBLN) on December 10, 2020. The report discloses the termination of a material consulting agreement and the approved transfer of the company's stock listing from the Nasdaq Global Market to the Nasdaq Capital Market.
Key Financial Metrics
The filing does not provide current revenue, profit, cash flow, or margin data. However, it references historical financial figures regarding listing compliance:
- Stockholders' Equity: Reported as $7,178,000 in the Form 10-Q for the quarter ended June 30, 2020.
- Consulting Fees: A total cash payment of $300,000 was agreed upon for a six-month consulting engagement ($50,000 per month), with the first installment already paid.
- Warrant Liability: A warrant to purchase 100,000 shares at an exercise price of $0.8285 remains outstanding.
Material Changes
Termination of Consulting Agreement
On December 11, 2020, the Company notified Blue Ox Healthcare Partners, LLC of its intent to terminate the Consulting Agreement dated August 11, 2020. The termination is effective January 10, 2021. While the consulting services will cease, the warrant issued to Blue Ox remains exercisable until August 10, 2025.
Listing Transfer
Nasdaq approved the transfer of the Company's common stock from the Nasdaq Global Market to the Nasdaq Capital Market, effective December 17, 2020. This action was taken because the Company failed to meet the $10,000,000 stockholders' equity requirement for the Global Market but met the $2,500,000 requirement for the Capital Market.
Outlook, Risks, and Contingencies
The Company remains non-compliant with the minimum bid price requirement (closing below $1.00 for 30 consecutive days) under Nasdaq Listing Rule 5450(a)(1). Upon transfer to the Capital Market, the Company retains the remainder of the 180-day compliance period (until February 2, 2021) to regain compliance. Compliance requires the bid price to close at $1.00 or more for 10 consecutive business days. Management states there can be no assurance that the Company will regain compliance or remain listed.
Investor Verification Checklist
- Verify the current stock price trend to assess the likelihood of meeting the $1.00 bid price requirement by February 2, 2021.
- Confirm the status of the outstanding warrant issued to Blue Ox Healthcare Partners, LLC (100,000 shares at $0.8285).
- Review the Company's capitalization strategy to ensure continued compliance with the $2,500,000 stockholders' equity requirement for the Nasdaq Capital Market.
- Monitor future filings for any updates on the outcome study and market strategy previously assigned to the terminated consultant.